Warning: Javascript must be enabled within your browser's settings for this site to function properly.

Your browser appears to be out of date, and is not supported by this site. For the best experience, we recommend that you upgrade to a more modern browser. You can find a list of modern browsers from www.browsehappy.com.

We use technical and analytics cookies data to ensure that we give you the best experience on our website. For more information visit our Privacy Page.

BWXT $   $  
As of . Minimum 20 minute delay.

News

BWX Technologies Reports Robust Second Quarter 2022 Results

08 August 2022

LYNCHBURG, Va.--(BUSINESS WIRE)-- BWX Technologies, Inc. (NYSE: BWXT) ("BWXT", "we", "us" or the "Company") reported second quarter 2022 revenue of $554 million, a 10% increase compared with $505 million in the second quarter 2021. GAAP net income for the second quarter 2022 was $74.6 million, or $0.82 per diluted share, compared with net income of $59.3 million, or $0.62 per diluted share, in the prior-year period. Non-GAAP(1) net income for the second quarter 2022 was $75.4 million, or $0.82 per diluted share. Adjusted EBITDA(1) for the second quarter 2022 was $114.7 million, a 26% increase compared with $90.8 million in the prior-year period, primarily driven by higher revenue, the timing of certain long lead material production and positive site performance. A reconciliation of non-GAAP(1) results are detailed in Exhibit 1.


BWXT Names Sharon H. Smoot as President of Nuclear Operations Group

27 July 2022

(LYNCHBURG, Va. – July 27, 2022) – BWX Technologies, Inc. (NYSE: BWXT) has appointed Sharon H. Smoot as president of BWXT’s Nuclear Operations Group, Inc. (NOG). In this role, she will have full responsibility for NOG’s mission to provide a complete range of nuclear components and services, including the manufacture of nuclear reactor components for U.S. Navy submarines and aircraft carriers and other nuclear and non-nuclear R&D and component production.




BWXT Medical Executes Commercial Agreement with Bayer for Supply of Actinium-225 Based Products

27 June 2022

(OTTAWA, ON – June 27, 2022) – BWX Technologies, Inc. (NYSE: BWXT) announced today that subsidiary BWXT Medical Ltd. has executed a commercial agreement with Bayer AG (Bayer) to supply high-purity Actinium-225 (Ac-225).


BWXT Medical and TRIUMF Execute Agreement for Manufacture of High Purity Ac-225 Based Products

13 June 2022

BWX Technologies, Inc. (NYSE: BWXT) announced today that subsidiary BWXT Medical Ltd. and TRIUMF, Canada’s particle accelerator centre, have executed a licensing and services agreement that strengthens their existing partnership for the production of medical isotopes.


BWXT to Build First Advanced Microreactor in United States

09 June 2022

(LYNCHBURG, Va. – June 9, 2022) – BWX Technologies, Inc. (NYSE: BWXT) will build the first advanced nuclear microreactor in the United States under a contract awarded by the U.S. Department of Defense (DoD) Strategic Capabilities Office (SCO). The Project Pele full-scale transportable microreactor prototype will be completed and delivered in 2024 for testing at the Idaho National Laboratory.


BWXT Names Ryan Colvert as Senior Director for Government Relations

16 May 2022

(LYNCHBURG, Va. – May 16, 2022) – BWX Technologies, Inc. (NYSE: BWXT) has hired Ryan B. Colvert as a senior director for government relations.



BWXT Appoints Jan A. Bertsch as New Chair of Board of Directors

03 May 2022

(LYNCHBURG, Va. – May 3, 2022) – BWX Technologies, Inc. (NYSE: BWXT) announced today that Jan A. Bertsch has been elected as its new chair of the board of directors, effective May 3, 2022, succeeding retiring board chairman John A. Fees.

Archive

Tags

Press Contacts:

BWX Technologies, Inc.

Jud Simmons 
+1 434.522.3800
hjsimmons@bwxt.com

BWXT Canada Ltd.  

Natalie Cutler 
+1 519.620.5288 
nacutler@bwxt.com 

BWXT Nuclear Energy Canada Inc.

Natalie Cutler
+1 519.620.5288  
nacutler@bwxt.com 

Nuclear Fuel Services, Inc.

Laura Bailey 
+1 423.743.9141
lebailey@nuclearfuelservices.com